Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership & People

Set Alert for Leadership & People

Executives On The Move: Oncorus, Orphazyme and More

Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.

Executive Changes Leadership

Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More

“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.

Leadership Policy

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.

Business Strategies Commercial

Executives On The Move: Kintor, Nexus and More

Recent executive moves in the industry include C-suite changes at Kintor Pharmaceutical and Antisense Therapeutics. Meanwhile, new directors were appointed at Nexus Pharmaceuticals and BiomX.

Executive Changes Leadership

Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout

Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.

M & A Deals

The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs

As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.

Strategy Sales & Earnings

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J’s Duarto on the importance of diversity; Teva’s views on its new risperidone launch; Almirall’s hopes for lebrikizumab; Biogen’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.

Leadership Diversity & Inclusion

Novartis Committed To Carving Out More Indications For Cosentyx

The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”

Immune Disorders Business Strategies

Executives On The Move: Grifols, Voyager and More

Recent executive moves in the industry include C-suite changes at Grifols and Zevra Therapeutics. Meanwhile, new directors were appointed at Voyager Therapeutics and Transgene.

Executive Changes Leadership

Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market

Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.

Launches Sales & Earnings

J&J CEO On Stereotypes, Innovation Secret Sauce And Kenvue

J&J chairman and CEO Joaquin Duato shares striking glimpses of his own life journey at a recent summit as he underscores the value of diversity, equity and inclusion. He also discusses the company’s formulae for innovation and the Kenvue spin out.

Commercial Leadership

Executives On The Move: Adagene, Provention and More

Recent executive changes in the industry include C-suite changes at Adagene and AstraZeneca. Meanwhile, new directors were appointed at Provention Bio and WPD Pharmaceuticals.

Executive Changes Leadership
See All
UsernamePublicRestriction

Register